Medical technology company Inogen Inc (Nasdaq:INGN) announcedon Thursday that it has entered a definitive agreement to purchase Physio-Assist SAS, a French company.
Physio-Assist's airway clearance device, Simeox, treats bronchiectasis, a lung condition common in cystic fibrosis and chronic obstructive pulmonary disease. The device has obtained CE mark clearance and is sold in Europe, Asia, and the Middle East.
The acquisition aims to diversify Inogen's portfolio and provide an innovative airway clearance solution for COPD and other chronic disease patients.
The cash transaction, valued at approximately USD32m, includes potential milestone payments of up to USD45m based on FDA clearance goals. The acquisition is expected to be accretive to gross margin in 2023 and to adjusted earnings from 2027 onwards.
The transaction is subject to customary closing conditions and is anticipated to close in Q4 2023.
As part of the deal, Inogen will provide Physio-Assist with a short-term loan of up to USD500,000, which will partially reduce the purchase price upon closing.
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant